184 related articles for article (PubMed ID: 26565547)
21. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
22. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
Tucker-Bartley A; Selen DJ; Golden E; van Gool R; Ebb D; Mannstadt M; Upadhyay J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768871
[TBL] [Abstract][Full Text] [Related]
24. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
[TBL] [Abstract][Full Text] [Related]
25. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Wehrhan F; Hyckel P; Amann K; Ries J; Stockmann P; Schlegel K; Neukam F; Nkenke E
Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807
[TBL] [Abstract][Full Text] [Related]
26. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
[TBL] [Abstract][Full Text] [Related]
27. [A case of osteonecrosis of the lower jaw due to bisphosphonates in a breast cancer patient with bone metastasis].
Kubo N; Katayama K; Ishizaki A; Morinaga N; Negishi T; Kuwano H
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1973-5. PubMed ID: 19011355
[TBL] [Abstract][Full Text] [Related]
28. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
29. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
Zervas K; Verrou E; Teleioudis Z; Vahtsevanos K; Banti A; Mihou D; Krikelis D; Terpos E
Br J Haematol; 2006 Sep; 134(6):620-3. PubMed ID: 16889620
[TBL] [Abstract][Full Text] [Related]
30. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
[TBL] [Abstract][Full Text] [Related]
31. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
32. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
Chan B; Zacharin M
J Pediatr Endocrinol Metab; 2006 Jan; 19(1):75-80. PubMed ID: 16509531
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate-induced osteonecrosis of the jaw.
Krueger CD; West PM; Sargent M; Lodolce AE; Pickard AS
Ann Pharmacother; 2007 Feb; 41(2):276-84. PubMed ID: 17299010
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.
Grant BT; Amenedo C; Freeman K; Kraut RA
J Oral Maxillofac Surg; 2008 Feb; 66(2):223-30. PubMed ID: 18201600
[TBL] [Abstract][Full Text] [Related]
35. Lesion Expansion in Gnathic Fibrous Dysplasia: Natural History, Indicators of Progression, and Response to Bisphosphonates.
Pan KS; Taylor J; Szymczuk V; Boyce AM
J Bone Miner Res; 2023 Oct; 38(10):1465-1471. PubMed ID: 37477421
[TBL] [Abstract][Full Text] [Related]
36. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
[TBL] [Abstract][Full Text] [Related]
37. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
Van Poznak C
Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
[TBL] [Abstract][Full Text] [Related]
38. [McCune-Albright syndrome revealed by Blaschko-linear café-au-lait spots on the back].
Jung AJ; Soskin S; Paris F; Lipsker D
Ann Dermatol Venereol; 2016 Jan; 143(1):21-6. PubMed ID: 26610360
[TBL] [Abstract][Full Text] [Related]
39. Osteonecrosis of the jaw: who gets it, and why?
Reid IR
Bone; 2009 Jan; 44(1):4-10. PubMed ID: 18948230
[TBL] [Abstract][Full Text] [Related]
40. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
